Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 24 Lung Neoplasms 14 Carcinoma, Medullary 14 Neoplasm Metastasis 12 Neoplasms 10 Thyroid Neoplasms 8 Breast Neoplasms 8 Glioma 6 Prostatic Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Gliosarcoma 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Thyroid Cancer, Papillary 2 Stomach Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Pleural Effusion 2 Kidney Neoplasms 2 Familial medullary thyroid carcinoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Disease Progression 2

Interventions

3-Iodobenzylguanidine 8 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Temozolomide 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 anlotinib 3 Everolimus 3 olaparib 2 cabozantinib 2 belzutifan 2 Sunitinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Biopsy 2 Axitinib 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 vandetanib 1 talazoparib 1 spartalizumab 1 pembrolizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fluorodopa F 18 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡